Art. 16 Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 Decembe…

In forcecited 1×
1.

In the case of the applications for marketing authorisation referred to in Articles 7 and 8 or the applications for waiver referred to in Articles 11 and 12, the paediatric investigation plan or the application for waiver shall be submitted with a request for agreement, except in duly justified cases, not later than upon completion of the human pharmaco-kinetic studies in adults specified in Section 5.2.3 of Part I of Annex I to Directive 2001/83/EC, so as to ensure that an opinion on use in the paediatric population of the medicinal product concerned can be given at the time of the assessment of the marketing authorisation or other application concerned.

2.

Within 30 days following receipt of the request referred to in paragraph 1 and in Article 15(1), the Agency shall verify the validity of the request and prepare a summary report for the Paediatric Committee.

3.

Whenever appropriate, the Agency may ask the applicant to submit additional particulars and documents, in which case the time-limit of 30 days shall be suspended until such time as the supplementary information requested has been provided.

  • Judgment of the General Court (Third Chamber) of 14 December 2011. Nycomed Danmark ApS v European Medicines Agency (EMA).Decision

    Articles 1, 2, 3, 6, 7, 11, 13, 15 and 16 of Regulation No 1901/2006 read as follows: ‘Article 1 This Regulation lays down rules concerning the development of medicinal products for human use in order to meet the specific therapeutic …

    14 Dec 2011 · 62009TJ0052